We use cookies to ensure that we give you the best website experience. By continuing to use this site, you are agreeing to our use of cookies.

Close
Loading images...
  • Kyowa Kirin

    Kyowa Kirin

    A global company committed to taking the walk of life, one life at a time

  • We bring innovative pharmaceuticals to the world

    We bring innovative pharmaceuticals to the world

    We are devoted to developing innovative antibody engineering technology by pursuing the truth of life more deeply.

  • "Therapeutic Antibodies" Hopes for the Future

    "Therapeutic Antibodies" Hopes for the Future

    We are devoted to developing innovative antibody engineering technology by pursuing the truth of life more deeply.

Kyowa Kirin, Inc. is a global specialty pharmaceutical company that applies state-of-the-art technologies to discover and deliver innovative medicines to meet the needs of patients. The U.S. organization includes three offices that focus on discovery, product development, and commercialization. As part of Kyowa Kirin Co., Ltd. with global headquarters in Tokyo, we aim to champion new solutions for patients and caregivers in four therapeutic areas: oncology, nephrology, immunology/allergy and neurology (CNS). Since 2018, the organization has received approval from the U.S. FDA to market three novel, first-in-class medicines – achievements we share with the scientific, medical and advocacy communities who contributed greatly to the success of these programs.


Sancuso

SANCUSO (granisetron transdermal system) was approved by the U.S. FDA in 2008 and has been used by thousands of patients.

Learn more at: sancuso.com
Read: Important Safety Information

Poteligeo

In 2018, the FDA approved POTELIGEO (mogamulizumab-kpkc injection) - a novel medicine based on Kyowa Kirin’s proprietary Potelligent® technology.

Learn more at: Poteligeo.com
Read: Important Safety Information

Nourianz

NOURIANZ (istradefylline), approved by the FDA in 2019, is the third novel, first-in-class product launched by Kyowa Kirin in the U.S. within 24 months.

Learn more at: Nourianz.com
Read: Important Safety Information